AVD-104 for Age-Related Macular Degeneration
(SIGLEC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is AVD-104 safe for humans?
What data supports the effectiveness of the drug AVD-104 for age-related macular degeneration?
Who Is on the Research Team?
David Callanan, MD
Principal Investigator
Aviceda Therapeutics
Are You a Good Fit for This Trial?
This trial is for people with a specific eye condition called Geographic Atrophy (GA) due to Age-Related Macular Degeneration (AMD). Participants must have certain levels of vision clarity, as measured by an eye chart. They should not have the wet form of AMD or other eye conditions that might need treatment during the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Part 1: Single Dose Treatment
Participants receive a single intravitreal injection of AVD-104 at one of 4 escalating doses and are followed for safety observation.
Part 2: Multiple Dose Treatment
Participants are randomized to receive either high dose AVD-104 bimonthly, low dose AVD-104 monthly, or avacincaptad monthly for 24 months.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AVD-104
- Sham injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aviceda Therapeutics, Inc.
Lead Sponsor